Target Information

Target General Infomation
Target ID
T95558
Former ID
TTDS00531
Target Name
Diacylglycerol O-acyltransferase 2
Gene Name
DGAT2
Synonyms
Diglyceride acyltransferase 2; DGAT2
Target Type
Successful
Disease Dyslipidaemias [ICD9: 272; ICD10: E78]
Lipid disorder; Cardiovascular disease [ICD9: 272, 390-459; ICD10: E78, I00-I99]
Function
Essential acyltransferase that catalyzes the terminal and only committed step in triacylglycerol synthesis by using diacylglycerol and fatty acyl CoA as substrates. Required for synthesis and storage of intracellular triglycerides. Probably plays a central role in cytosolic lipid accumulation. In liver, is primarily responsible for incorporating endogenously synthesized fatty acids into triglycerides (By similarity). Functions also as an acyl-CoA retinol acyltransferase (ARAT).
BioChemical Class
Acyltransferase
UniProt ID
Q96PD7
EC Number
EC 2.3.1.76
Sequence
MKTLIAAYSGVLRGERQAEADRSQRSHGGPALSREGSGRWGTGSSILSALQDLFSVTWLN
RSKVEKQLQVISVLQWVLSFLVLGVACSAILMYIFCTDCWLIAVLYFTWLVFDWNTPKKG
GRRSQWVRNWAVWRYFRDYFPIQLVKTHNLLTTRNYIFGYHPHGIMGLGAFCNFSTEATE
VSKKFPGIRPYLATLAGNFRMPVLREYLMSGGICPVSRDTIDYLLSKNGSGNAIIIVVGG
AAESLSSMPGKNAVTLRNRKGFVKLALRHGADLVPIYSFGENEVYKQVIFEEGSWGRWVQ
KKFQKYIGFAPCIFHGRGLFSSDTWGLVPYSKPITTVVGEPITIPKLEHPTQQDIDLYHT
MYMEALVKLFDKHKTKFGLPETEVLEVN
Drugs and Mode of Action
Drug(s) Vitamin B3 Drug Info Approved Lipid disorder; Cardiovascular disease [526373]
ARI-3037MO Drug Info Phase 1 Dyslipidaemias [550270]
Inhibitor ARI-3037MO Drug Info [550270]
Vitamin B3 Drug Info [526373]
Pathways
BioCyc Pathway Triacylglycerol biosynthesis
KEGG Pathway Glycerolipid metabolism
Metabolic pathways
Fat digestion and absorption
Reactome Acyl chain remodeling of DAG and TAG
Triglyceride Biosynthesis
WikiPathways Triacylglyceride Synthesis
Glycerophospholipid biosynthesis
Fatty acid, triacylglycerol, and ketone body metabolism
References
Ref 526373Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE: The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002 Jul;147(1):20-31.
Ref 5502702011 Pipeline of Arisaph Pharmaceuticals.
Ref 526373Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE: The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002 Jul;147(1):20-31.
Ref 5502702011 Pipeline of Arisaph Pharmaceuticals.
Ref 1587926URL: https://www.ebi.ac.uk/chembl/ The ChEMBL database in 2017

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.